Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey

Icatibant is used to treat acute hereditary angioedema with C1 inhibitor deficiency types I/II (C1‐INH‐HAE types I/II) and has shown promise in angioedema due to acquired C1 inhibitor deficiency (C1‐INH‐AAE). Data from the Icatibant Outcome Survey (IOS) were analysed to evaluate the effectiveness of...

Descripción completa

Detalles Bibliográficos
Autores principales: Longhurst, H. J., Zanichelli, A., Caballero, T., Bouillet, L., Aberer, W., Maurer, M., Fain, O., Fabien, V., Andresen, I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5343339/
https://www.ncbi.nlm.nih.gov/pubmed/27936514
http://dx.doi.org/10.1111/cei.12910

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5343339/
https://www.ncbi.nlm.nih.gov/pubmed/27936514
http://dx.doi.org/10.1111/cei.12910

Ejemplares similares